Selected Publications

Bargou R, Leo E (shared first authorship), Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle PA, Kufer P.
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.
Science 2008; 321(5891):974-7.

McClanahan F, Hielscher T, Rieger M, Hensel M, Bentz M, Schmidt-Wolf I, Käbisch A, Salwender H, Dürk H, Staiger H, Mandel T, Neben K, Hillengass J, Leo E, Krämer A, Ho AD, Witzens-Harig M.
Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma.
Am J Hematol. 2012 Oct;87(10):E68-71

Levis M, Perl AE, Dombret H, Döhner H, Steffen B, Rousselot P, Martinelli G, Estey EH, Burnett AK, Gammon G, Trone D, Leo E, Cortes JE
Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation
American Society of Hematology 2011; Annual Meeting

Cortes JE, Perl AE, Dombret H, Kayser S, Steffen B, Rousselot P, Martinelli G, Estey EH, Burnett AK, Gammon G, Trone D, Leo E, Levis MJ
Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia.
American Society of Hematology 2011; Annual Meeting

Stühmer T, Arts J, Chatterjee M, Borawski J, Wolff A, King P, Einsele H, Leo E, Bargou RC.
Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585.
Br J Haematol 2010;149(4):529-36

Stuehmer T, Arts J, King P, Page M, Bommert K, Leo E, Bargou RC
A first-in-class HDM2-inhibitor (JNJ-26854165) in phase I development shows potent activity against multiple myeloma (MM) cells in vitro and ex vivo.
J Clin Oncol 2008; Suppl 26; May 20; #14694

Stuehmer T, Arts J, King P, Borawski J, Page M, Leo E, Bargou RC
Preclinical evaluation of the novel HDAC-inhibitor JNJ-26481585 in multiple myeloma reveals strong anti-tumor activity
American Association for Cancer Research 2008; Annual Meeting, #738

Arts J, Page M, Valckx A, Blattner C, Kulikov R, Floren W, van Nuffel L, Janssen L, King P, Masure S, Smans K, Verhasselt P, Goehlmann H, Ligny Y, Lardeau D, Csoka I, Andries L, Brehmer D, Freyne E, Leo E, Janicot M, Meyer C, Lacrampe J, Schoentjes B
JNJ-26854165 – a novel hdm2 antagonist in clinical development showing broad-spectrum preclinical antitumor activity against solid malignancies.
American Association for Cancer Research 2008; Annual Meeting, # 1592

Leo E
Are There Ways to Truly Accelerate Early Drug Development?
“Latest Advances on Anticancer Drugs in Clinical Development”
5th European Spring Oncology Conference; Marbella, Málaga, Spain. June 26, 2008

Tabernero J, Schöffsky P, Dirix L, Capdevila J, Dumez H, Kraljevic S, Bol K, Winkler H, de Bie L, Rooney B, Arts J, Leo E
First-in-human study of the first-in-class Hdm2 inhibitor JNJ-26854165.
Annual EORTC-NCI-AACR Conference on “Molecular targets and cancer therapeutics” 2008, Geneva.

Oberneder R, Weckermann D, Ebner B, Quadt, Kirchinger P, Raum T, Locher M, Prang N, Baeuerle PA, Leo E
A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients
Eur J Cancer 2006; 42(15):2530-8

Schmitt C, Grundt A, Buchholtz C, Scheuer L, Benner A, Hensel M, Ho AD, Leo E
One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?
Leukemia Res 2006; 30(12):1563-8

Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N, Brandl C, Lippold S, Cobb K, Brasky K, Leo E, Bargou R, Murthy K, Baeuerle PA
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Cancer Immunol Immunother 2006; May;55(5):503-14.

Leo E, Deveraux Q, Buchholtz C, Welsh K, Matsuzawa S, Stennicke H, Salvesen GS, Reed JC
TRAF1 is cleaved by caspases during TNF- and FAS-mediated apoptosis.
J Biol Chem 2001; Mar 16;276(11):8087-93.

Ni CZ, Welsh K, Leo E, Chiou CK, Wu H, Reed JC, Ely KE
Crystal structure of the signaling protein TRAF3 bound to a fragment of CD40.
Proc Natl Acad Sci 2000; 97(19):10395-9

Zapata JM, Matsuzawa S, Godzik A, Leo E, Wasserman SA, Reed JC
The drosophila tumor necrosis factor recetor-associated factor-1 (D-TRAF1) interacts with pelle and regulates NF-kB activity.
J Biol Chem 2000; 275(16):12102-7

Leo E, Zapata JM, Reed JC
CD40-Mediated activation of Ig-Cg1-and Ig-Ce-germline promoters involves multiple TRAF-family proteins.
Eur J Immunol 1999; 29(12):3908-13

Ye X, Mehlen P, Rabizadeh S, VanArsdale T, Zhang H, Shin H, Wang JJ, Leo E, Zapata J, Hauser CA, Reed JC, Bredesen DE
TRAF family proteins interact with the common neurotrophin receptor and modulate apoptosis induction.
J Biol Chem 1999 ; 274(42):30202-8

Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC
Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases.
EMBO J 1999; 18(19):5242-51

Leo E, Welsh K, Matsuzawa S, Zapata JM, Kitada S, Mitchell RS, Ely KR, Reed JC
Differential requirements for tumor necrosis factor receptor-associated factor family proteins in CD40-mediated induction of NF-kappaB and JunN-terminal kinase activation.
J Biol Chem 1999; 274(32):22414-22


LEOconsulting-Pubication list